RHYTHM PHARMACEUTICALS, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
RHYTHM PHARMACEUTICALS, INC. (RYTM) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $427.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-04
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $427.00K.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $641.00K.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $214.00K.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $427.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $427.00K 10-Q · filed 2026-08-04 |
| 2026-03-31 | $641.00K 10-Q · filed 2026-05-05 |
| 2025-09-30 | $214.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | $427.00K 10-Q · filed 2025-08-05 |
| 2025-03-31 | $641.00K 10-Q · filed 2025-05-07 |
| 2023-09-30 | $214.00K 10-Q · filed 2023-11-08 |
| 2023-06-30 | $428.00K 10-Q · filed 2023-08-01 |
| 2023-03-31 | $641.00K 10-Q · filed 2023-05-02 |
| 2022-09-30 | $214.00K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $425.00K 10-Q · filed 2022-08-03 |
| 2022-03-31 | $641.00K 10-Q · filed 2022-05-03 |
| 2021-09-30 | $114.00K 10-Q · filed 2021-11-02 |
| 2021-06-30 | $228.00K 10-Q · filed 2021-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |